Management of dermatoses with topical clobetasol propionate 0.025%

Authors

  • Maragondanahalli G. Gopala Department of Dermatology, Sree Venkateshwara Skin Clinic, Bangalore, Karnataka, India
  • Sidramappa R. Warad Department of Dermatology, Best Skin Clinic, Bijapur, Karnataka, India
  • Manas R. Puhan Department of Dermatology, Niki Skin Care, Cuttack, Odisha, India
  • Saurabh Agrawal Department of Dermatology, Saurabh Agrawal Clinic, Bikaner, Rajasthan, India
  • Sanjay J. Parbhani Department of Dermatology, Jogad Skin and Laser Center, Parbhani, Maharashtra, India
  • Kavita Mehendiratta Department of Dermatology, Dr. Kavita Skin Clinic, Faridabad, Haryana, India
  • Mahaveer P. Gupta Department of Dermatology, Medical Center, Jaipur, Rajasthan, India
  • Farhana T. Taj Department of Dermatology, KLE Deemed University, JNMC Campus, Belagavi, Karnataka, India
  • Vamja Chirag Department of Dermatology, Kalarav Hospital, Amreli, Gujarat, India
  • Satish D. A. Department of Dermatology, Skin Cosmetic and ENT Care Center, Bengaluru, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20220525

Keywords:

Clobetasol propionate 0.025%, Topical corticosteroid, Plaque psoriasis, Psoriasis

Abstract

The development of topical corticosteroids (TC) has enabled effective treatment of many dermatoses. The main therapeutic activity of topical corticosteroids is their nonspecific anti-inflammatory effect that primarily seems to be a result of their action on the chemical mediators of inflammation. Topical corticosteroids have also been shown to be antimitotic. Corticosteroids also play a vital role in cellular signaling, immune function and protein regulation. Clobetasol propionate (CP) 0.025% is a prescription corticosteroid medicine, used to treat moderate to severe plaque psoriasis in patients 18 years of age and older. It is a class I specialized cream formulation, that is free of propylene glycol, short-chain alcohols (e.g. ethanol), and sorbitan sesquioleate, a sorbitol-based emulsifier which is a common contact allergen used in many topical corticosteroid formulations. This case series discusses about management of different dermatoses using ImpoyzTM (clobetasol propionate) cream 0.025%.

References

Sterry W. Therapy with topical corticosteroids. Arch Dermatol Res. 1992;284(1):27-9.

Del Rosso Do JQ. Combination topical therapy for the treatment of psoriasis. J Drugs Dermatol. 2006;5(3):232-4.

Del Rosso JQ. Topical corticosteroid therapy for psoriasis—a review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Sukarovska BG, Lipozencic J, Vrzogic P. Topical corticosteroids and corticosteroid sparing therapy in psoriasis management. Acta Med Croatica. 2007;61(4):375-81.

Impoyz TM (clobetasol propionate) Cream. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209483Orig1s000MedR.pdf. Accessed on 10 December 2021.

Downloads

Published

2022-02-25

How to Cite

Gopala, M. G., Warad, S. R., Puhan, M. R., Agrawal, S., Parbhani, S. J., Mehendiratta, K., Gupta, M. P., Taj, F. T., Chirag, V., & A., S. D. (2022). Management of dermatoses with topical clobetasol propionate 0.025%. International Journal of Research in Medical Sciences, 10(3), 717–722. https://doi.org/10.18203/2320-6012.ijrms20220525

Issue

Section

Case Series